We are determined to realize the
promise of precision medicine.

About Our Company

HI-Bio™ was founded on the idea that therapies for immune-mediated diseases (IMDs) have the potential to achieve better results for patients.

Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes. HI-Bio’s programs apply a precision medicine approach to target, modulate or deplete these cellular drivers of disease with therapeutics.

HI-Bio is applying a precision medicine approach. Now is the time for medicines that use genetic and immunological insights to transform the lives of patients with severe IMDs.


Sunil Agarwal, M.D.Former Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology
Paul BernsChairman of the Board, HI-Bio and Managing Director at ARCH Venture Partners
Fred Cohen, M.D., D.Phil.Co-Founder and Chairman at Monograph Capital Partners
Chris DimitropoulosManaging Director of Healthcare Investments at Alpha Wave Global
Barbara Krebs-Pohl, Ph.D.Chief Business Officer at MorphoSys
Rachel Mears, J.D.Partner at Jeito Capital
Mark Murcko, Ph.D.Founding Chief Scientific Officer at Dewpoint Therapeutics and Relay Therapeutics
Travis Murdoch, M.D.Chief Executive Officer
Carol SuhPartner at ARCH Venture Partners


undefined undefined
undefined undefined
undefined undefined
Contact Us